The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with HER2-mutant advanced NSCLC.
 
Joshua Sabari
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech/Roche; Janssen; Janssen (Inst); Loxo/Lilly; Loxo/Lilly (Inst); Medscape; Mirati Therapeutics; Mirati Therapeutics (Inst); Pfizer; Regeneron; Regeneron (Inst); Sanofi; Takeda
 
Gerrina Ruiter
Consulting or Advisory Role - Boehringer Ingelheim (Inst)
Speakers' Bureau - AstraZeneca (Inst); Boehringer Ingelheim (Inst)
 
Ernest Nadal
Honoraria - Apollomics; Roche/Genentech; Transgene
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Genmab; Janssen Oncology; Lilly; Merck Serono; MSD; Pfizer; Pierre Fabre; Qiagen; Roche; Sanofi; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Takeda
 
Lizza Hendricks
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Takeda (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bayer (Inst); Benecke; GlaxoSmithKline (Inst); high5oncology (Inst); Lilly (Inst); Medimix; Medtalks; MSD (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst); VJOncology
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Other Relationship - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Towa Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Kyowa Kirin International; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Summit Health; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Hannah Fairbanks
No Relationships to Disclose
 
Heiko Zettl
Employment - Boehringer Ingelheim
 
Alexandra Lauer
Employment - Boehringer Ingelheim
Honoraria - Goethe Universitat, Frankfurt am Main
 
Behbood Sadrolhefazi
Employment - Boehringer Ingelheim